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Oxygen uptake before and after the onset of
claudication during a 6-minute walk test
Andrew W. Gardner, PhD,a,b Raphael M. Ritti-Dias, PhD,c Julie A. Stoner, PhD,d
Polly S. Montgomery, MS,a Aman Khurana, MD,b,e and Steve M. Blevins, MD,f Oklahoma City, Okla;
and Recife, Pernambuco, Brazil
Objective: This study compared oxygen uptake before and after the onset of claudication in individuals with peripheral
artery disease (PAD) during a 6-minute walk test, and identified predictors of the change in oxygen uptake after the onset
of claudication pain.
Methods: The study included 50 individuals with PAD. During a 6-minute walk test, 33 experienced claudication (pain
group), and 17 were pain-free (pain-free group). Oxygen uptake and ambulatory cadence were the primary outcomes
evaluated during the 6-minute walk test.
Results: The pain group experienced onset of claudication pain at a mean (standard deviation) of 179 (45) meters and
continued to walk to achieve a 6-minute walk distance of 393 (74) meters, which was similar to the 401 (76) meters
walked in the pain-free group (P  .74). Oxygen uptake increased (P < .0001) after the onset of pain in the pain group,
and this change was greater (P  .025) than the increase in oxygen uptake from the second to fifth minutes of walking
in the pain-free group. Ambulatory cadence decreased after the onset of pain in the pain group (P  .0003). The change
in oxygen uptake was associated with metabolic syndrome (P  .0023), 6-minute walk distance (P  .0037), age (P 
.0041), and oxygen uptake during the second minute of the test (P  .012).
Conclusion: Claudication increases oxygen uptake of self-paced, over-the-ground ambulation, despite a decrease in
cadence. The pain-mediated increase in oxygen uptake was blunted in individuals with metabolic syndrome, suggesting
that the ability to increase oxygen uptake during ambulation is impaired. The clinical significance is that claudication
increases the metabolic cost of ambulation, thereby increasing the relative intensity of exercise and reducing the tolerance
to sustain ambulation. (J Vasc Surg 2011;54:1366-73.)
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MPeripheral artery disease (PAD) is prevalent in12% of
the U.S. population aged65 years1 and is associated with
elevated rates of mortality2-5 and morbidity,6 because
60% of these individuals have concomitant cardiovascular
or cerebrovascular disease, or both.7 In addition, many of
those with PAD are physically limited by ambulatory leg
pain. Claudication is prevalent in 6% of those aged 65
years,1,7 which results in impaired ambulation,8,9 reduced
physical function,10,11 and lower daily physical activity.12
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1366Less is known about how the onset of claudication
cutely affects ambulation. Oxygen uptake is increased with
he onset of claudication during treadmill exercise at con-
tant load, thereby increasing the relative metabolic cost of
ainful ambulation and reducing exercise tolerance.13
hether the increase in oxygen uptake after pain onset
uring treadmill walking is evident during self-paced, over-
he-ground ambulation is not clear because individuals may
ompensate by slowing their pace14,15 to maintain a given
etabolic cost. However, slowing freely-chosen velocity by
oo much results in less economic ambulation,16-18 which
ay increase oxygen uptake even further during painful
mbulation. The oxygen uptake of self-paced, over-the-
round ambulation during pain-free and painful ambulation,
hich has not been previously examined, has important im-
lications regarding the intensity at which ambulation is per-
ormed in the community setting.
This study compared oxygen uptake before and after
he onset of claudication in individuals with PAD during a
-minute walk test (6-MWT), and identified predictors of
he change in oxygen uptake after the onset of claudication
ain. We hypothesized that oxygen uptake would increase
fter the onset of claudication and that the severity of PAD
nd the change in ambulatory cadence and velocity would
redict the change in oxygen uptake after the onset of
laudication.
ETHODS
The procedures used in this study were approved by the
nstitutional Review Board at the University of Oklahoma
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Volume 54, Number 5 Gardner et al 1367Health Sciences Center (UOHSC). Written informed con-
sent was obtained from each participant before the investi-
gation.
Participant recruitment. Study participants were eval-
uated in the General Clinical Research Center at the
UOHSC. Participants were recruited by referrals from the
HSC Vascular Clinic and by newspaper advertisements for
possible enrollment into a randomized controlled exercise
rehabilitation study.19 The data and analyses for this study
were part of the baseline assessments obtained for the
exercise study.
Screening. Individuals with claudication secondary to
vascular insufficiency were included in this study if they had
(1) a history of any type of exertional leg pain, (2) ambu-
lation during a graded treadmill test limited by leg pain
consistent with claudication,8 and (3) an ankle-brachial
index (ABI) 0.90 at rest1,7 or an ABI 0.73 after exer-
cise, because some PAD patients have normal values at rest
which only become abnormal after an exercise test.20 Ex-
clusion criteria were:
1. Absence of PAD (ABI 0.90 at rest and ABI 0.73
after exercise);
2. Inability to obtain an ABImeasure due to noncompress-
ible vessels;
3. Asymptomatic PAD (Fontaine stage I) determined from
themedical history and verified during the graded tread-
mill test;
4. Use of medications indicated for the treatment of clau-
dication (cilostazol and pentoxifylline) initiated 3
months before the investigation;
5. Exercise tolerance during maximal treadmill exercise
limited by factors other than claudication pain, such as
severe coronary artery disease, dyspnea, and poorly con-
trolled blood pressure;
6. Active cancer, end-stage renal disease, or liver disease;
7. Discontinuing ambulation for any reason during the
6-MWT; and
8. For those experiencing pain during the 6-MWT, ambu-
lating for1 complete minute during pain-free or pain-
ful conditions because an insufficient amount of data
was available for analyses.
The study evaluated 77 individuals, and 50 were deemed
eligible. Demographic information, height, weight, body
mass index (BMI), waist and hip circumferences,21 cardio-
vascular risk factors, comorbid conditions, claudication his-
tory, blood samples, and a list of current medications were
obtained from a medical history and physical examination
at the beginning of the study.
Measurements. Primary outcome measures were ox-
ygen uptake and ambulatory cadence obtained during the
6-MWT.
Procedures. A trained technician administered the
over-the-ground, 6-MWT in which two cones were placed
100 feet apart in a marked corridor, as previously de-
scribed.22 Participants were instructed to walk as many laps
around the cones as possible while wearing a light-weight
(0.8-kg) portable oxygen uptake unit (COSMED K4 b2, aOSMED USA, Inc, Chicago, Ill), which continuously
easured oxygen uptake via indirect calorimetry. Partici-
ants also wore a step activity monitor (Step Watch 3,
yma Inc, Mountlake Terrace, Wash) on their right ankle.
During the test, participants indicated if and when they
xperienced the onset of claudication pain. Those who
xperienced pain during the 6-MWT (pain group) were
ompared with those who completed the test without pain
pain-free group), as described subsequently in the Results.
rimary outcome measures
The 6-MWT was the experimental protocol used to
btain the primary outcome measures of oxygen uptake
nd ambulatory cadence, and other measures consisting of
tride length, ambulatory velocity, time and distance to
nset of pain, and total 6-minute walk distance (6-MWD).
xygen uptake and ambulatory cadence were obtained
ach minute during the test, and the technician recorded
he time and distance to onset of claudication and the total
istance walked. Walking distances were converted from
eet to meters.
Oxygen uptake and ambulatory cadence. These val-
es obtained during the first and last minute of exercise in
ither group were not used for analyses because of the
ossibility that data were not recorded for a full 60 seconds
uring these time points. In the pain group, oxygen uptake
nd ambulatory cadence obtained during the minute in
hich the onset of claudication occurred was not used for
nalyses because it was not possible to precisely separate the
ata before and after the onset of pain within the minute.
Stride length and ambulatory velocity. These values
ere calculated in the pain group during pain-free and
ainful ambulation. However, these calculations were not
ossible to determine during the test in the pain-free group
ecause (1) the participants did not experience claudica-
ion, and therefore, ambulation did not occur under painful
onditions; and (2) time and distance measures were not
ecorded at specified intervals because of concerns that this
dditional encumbrance on the technician while the test
as proceeding might affect the results of the self-paced
MWT. Therefore, the calculation of stride length and
mbulatory velocity at different times during the test in the
ain-free group was not possible.
Change scores for oxygen uptake and gait parameters
ere calculated as the difference in average values obtained
uring painful ambulation minus the values obtained dur-
ng pain-free ambulation in the pain group, and as the
ifference between the values at 5 minutes minus the values
t 2 minutes during exercise in the pain-free group.
econdary outcome measures
Walking Impairment Questionnaire. Self-reported
mbulatory ability was obtained using the Walking Impair-
ent Questionnaire (WIQ), which has been validated for
AD patients, that assesses ability to walk at various speeds
nd distances, and to climb stairs.23
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November 20111368 Gardner et alClaudication times and peak oxygen uptake during
graded treadmill test. Participants performed a progres-
sive, graded treadmill protocol to determine study eligibil-
ity and to obtain outcome measures related to exercise
performance.8 The claudication onset time, defined as the
walking time at which the individual first experienced pain,
and the peak walking time, defined as the walking time at
which ambulation could not continue due to maximal pain,
were both recorded to quantify the severity of claudication.
Peak oxygen uptake was measured by oxygen uptake ob-
tained during the peak exercise workload with a Medical
Graphics VO2000 metabolic system (Medical Graphics
Inc, St Paul, Minn). The test–retest intraclass reliability
coefficient for these methods is R  .89 for claudication
onset time,8 R  .93 for peak walking time,8 and R  .88
for peak oxygen uptake.24
ABI and ischemic window. As previously described,
ABI measures were obtained from the more severely dis-
eased leg before and 1, 3, 5, and 7 minutes after the
treadmill test.8,25 The reduction in ankle systolic blood
pressure after treadmill exercise from the resting baseline
value was quantified by calculating the area under the
curve, referred to as the ischemic window.26 Because
the ischemic window is a function of both PAD severity and
the amount of exercise performed, the ischemic window
was normalized per meter walked.
Ambulatory activity monitoring. Daily ambulatory
activity was assessed using a step activity monitor, as previ-
ously described.27 Ambulatory activity was measured dur-
ing 7 consecutive days in which participants were instructed
to wear the monitor during waking hours and to remove it
before retiring to bed. The step activity monitor was at-
tached to the right ankle above the lateral malleolus using
elastic Velcro straps and continuously recorded the number
of steps taken minute-to-minute. The accuracy of the step
activity monitor exceeds 99%  1% in individuals with
claudication.27
Statistical analyses. An independent sample t test was
used to compare the means of continuous demographic
and clinical measures between the pain group and the
pain-free group. A 2 test, or Fisher exact test for small,
expected data cell counts, was used to compare the distri-
bution of categoric demographic and clinical measures
between the two groups.
To address the first aim, a non-parametric Wilcoxon
signed rank test was used to compare the median oxygen
uptake measures and the median ambulatory parameters
(cadence, speed, and stride length) between pain-free and
painful ambulation in the pain group and between minutes
2 and 5 in the pain-free group. An independent sample
Wilcoxon rank sum test was used for between-group com-
parisons of the distribution of changes in oxygen uptake
and ambulatory parameters. For the pain-free time dur-
ing the 6-MWT, between-group comparisons of mean
values to a fixed reference were made using a one-sample
t test. A two-sided   0.05 was used to define statistical
significance. tTo address the second aim, linear regression was used
o identify clinical and exercise performance characteristics
hat were independently associated with oxygen uptake
fter adjustment for height. Clinical and exercise perfor-
ance characteristics associated with oxygen uptake uni-
ariately at an   0.05 level were entered into a multiple
inear regression model. Clinical and exercise performance
haracteristics were deleted from the multiple regression
odel until all terms were significant at the   0.05 level.
he clinical and exercise performance characteristics that
ere considered in the modeling are listed in Table I and
able II. Height was adjusted for in the regression model
o adjust for the association between height and stride rate.
ata were analyzed using SAS 9.1 software (SAS Institute
nc, Cary, NC) and SPSS 15.0 software (SPSS Inc, Chi-
ago, Ill).
ESULTS
Participants were grouped according to whether they
id (pain group; n  33) or did not (pain-free group; n 
7) experience claudication during the 6-MWT. The
roups were similar on all clinical characteristics (P .05),
xcept that the pain group had higher body weight (P 
038) and a nonsignificant trend for a higher prevalence of
etabolic syndrome (P .070; Table I). The groups were
imilar on all measures of treadmill exercise performance,
IQ measures, and daily ambulatory activity (P  .05;
able II), but the pain group, by definition, had shorter
-minute walk pain-free time (P  .001) and pain-free
istance (P  .001) than the pain-free group (Table III).
Oxygen uptake during pain-free ambulation increased
P  .0001) after the onset of pain in the pain group, and
able I. Clinical characteristics of study participants
ariable
Pain group Pain-free group
P
(n  33) (n  17)
Mean (SD) Mean (SD)
ge, years 65 (9) 67 (11) .59
eight, kg 89.6 (18.7) 78.0 (17.4) .038
eight, cm 171.0 (9.7) 169.2 (9.1) .51
ody mass index, kg/m2 30.6 (5.8) 27.6 (7.6) .12
aist girth, cma 105.1 (16.0) 102.6 (18.2) .74
nkle/brachial index 0.72 (0.20) 0.75 (0.21) .61
Percentage Percentage
ex, men 67 59 .58
hite race 61 47 .36
urrent smoking 36 35 .94
iabetes 36 41 .74
ypertension 88 76 .42
yperlipidemia 76 82 .73
bdominal obesitya 63 71 .99
besity 48 29 .20
etabolic syndrome 88 65 .070
D, Standard deviation.
This measurement included 19 in the pain group and 7 in the pain-free
roup.his change was greater (P  .025) than the increase in
t
p
W
u
p
i
p
p
i
r
a
s
i
p
t
i
c
f
m
a
c
g
r
b
c
n
c
s
t
t
fi
t
i
e
t
a
JOURNAL OF VASCULAR SURGERY
Volume 54, Number 5 Gardner et al 1369oxygen uptake from minutes 2 to 5 of walking in the
pain-free group (Fig 1, Table IV). In contrast, the decrease
in ambulatory cadence after pain onset in the pain group
(P .0003) was similar (P .79) to the decline in cadence
from minutes 2 to 5 of walking in the pain-free group
(Table IV). After pain onset, the pain group also experi-
enced a shorter stride length (P  .0001), a decline in
ambulatory velocity (P  .0001), and increased oxygen up-
take when expressed per stride taken (P  .0001) or meter
walked (P .0001) than before pain onset (Table IV).
Themultiple regressionmodel predicting the change in
oxygen uptake after the onset of claudication in patients in
the pain group is presented in Table V. Metabolic syn-
drome was negatively associated with the increase in oxy-
gen uptake after pain onset, because individuals with met-
abolic syndrome had on average a 1.83 mL/kg/min lower
change in oxygen uptake than those without metabolic
syndrome (Fig 2). In contrast, age, 6-MWD, and the
oxygen uptake during the second minute of the 6-MWT
were positively associated with the pain-mediated increase
in oxygen uptake.
DISCUSSION
Changes in oxygen uptake and ambulatory cadence
during painful ambulation. The primary finding was that
oxygen uptake increased by 36% after the transition from
pain-free to painful ambulation during the 6-MWT. This
Table II. Treadmill exercise performance, Walking Impair
of participants
Variable
Pa
(n
Me
Claudication onset time, seconds 24
Peak walking time, seconds 47
Peak oxygen uptake, mL/kg/minute 13.
Ischemic window, mm Hg  minute/m 0.5
Walking Impairment Questionnaire
Distance score, % 3
Speed score, % 3
Stair climbing score % 4
Daily ambulatory activity, strides/day 371
SD, Standard deviation.
Table III. Six-minute walk test (6-MWT) measurements
of participants
6-MWT variables
Pain group Pain-free group
P
(n  33) (n  17)
Mean (SD) Mean (SD)
Pain-free time, seconds 156 (29) 360 (0) .0001a
Pain-free distance, m 179 (45) 401 (76) .0001
Walk distance, m 393 (74) 401 (76) .74
SD, Standard deviation.
aComparison made between 6-MWT pain-free time in the pain group and a
fixed value of 360 seconds in the pain-free group using a one-sample t test.observation supports a previous report from our laboratory ihat that oxygen uptake was higher while ambulating with
ain during a constant-speed, standardized treadmill test.13
hether the observed pain-mediated increase in oxygen
ptake during treadmill exercise would occur during self-
aced, over-the-ground ambulation was not clear because
ndividuals can attempt to compensate by slowing their
ace.
We found that ambulatory cadence decreased during
ainful ambulation, supporting previous reports of changes
n gait measures after the onset of claudication, such as
educed ambulatory velocity,15 shortened step length,15
nd decreased ankle plantar flexor moments14 at self-
elected pace over short distances. However, the reduction
n ambulatory cadence during painful ambulation in the
resent study did not reduce the metabolic cost of walking.
Although this study does not address mechanisms for
he increase in oxygen uptake during painful ambulation, it
ndicates that a given exercise work rate becomes more
hallenging to perform than pain-free ambulation. Muscle
orce production decreases with claudication,28,29 which
ay explain the decrease in stride length during painful
mbulation in the pain group. It is possible that the de-
rease in stride length during the test was greater in the pain
roup than in the pain-free group, and this may be one
eason why the increase in oxygen uptake was not different
etween the two groups when expressed per stride taken.
When muscle force production decreases with claudi-
ation, the recruitment of more motor units per muscle is
eeded to generate the required force to ambulate.18 A
hange in muscle fiber recruitment patterns would be con-
istent with more challenging ambulation,18 suggesting
hat more motor units—particularly more fast-twitch mo-
or units, which are less economical than slow-twitch
bers30—are recruited to perform painful ambulation. Fur-
hermore, the muscle denervation observed in PAD partic-
pants31 may impair optimal motor unit recruitment during
xercise, becoming more evident during painful ambula-
ion.
Those who completed the 6-MWT pain-free also had
n increase in oxygen uptake during exercise, but the
t Questionnaire measures, and daily ambulatory activity
up Pain-free group
P
) (n  17)
D) Mean (SD)
8) 265 (214) .68
4) 438 (212) .55
) 12.6 (3.1) .40
5) 0.47 (0.62) .74
) 45 (35) .56
) 42 (25) .30
) 42 (31) .73
11) 3688 (1920) .96men
in gro
 33
an (S
0 (17
5 (19
5 (3.5
2 (0.4
9 (30
5 (20
5 (29
9 (18ncrease was smaller than the increase in those who per-
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November 20111370 Gardner et alformed painful ambulation. A gradual increase in oxygen
uptake has been observed during intense exercise compared
with light exercise, thus preventing oxygen uptake from
reaching a steady-state plateau during exercise at a constant
Fig 1. Box and whisker plots show the change in oxyge
(n  33) and the pain-free group (n  17). The change
painful ambulation minus the VO2 during pain-free amb
VO2 measured during the fifth minute minus the VO2 m
middle of each box indicates the median; the top and bo
respectively; and the whiskers mark the minimum and ma
Table IV. Oxygen uptake (VO2) and gait measures during
free group (n  17)
Variablesa Time 1b Time 2
VO2, mL/kg
Per minute
Pain group 8.4 (6.6 to 9.6) 11.4 (10.1 to
Pain-free group 8.4 (7.5 to 10.2) 11.0 (10.2 to
Per meter walked
Pain group 0.10 (0.08 to 0.12) 0.14 (0.12 to
Pain-free group . . . . . .
Per stride taken
Pain group 0.18 (0.15 to 0.20) 0.21 (0.19 to
Pain-free group 0.17 (0.13 to 0.20) 0.21 (0.19 to
Velocity, m/minute
Pain group 66.6 (61.8 to 75.5) 65.9 (53.5 to
Pain-free group . . . . . .
Cadence, strides/minute
Pain group 55.0 (52.0 to 56.0) 54.0 (50.5 to
Pain-free group 53.0 (50.0 to 56.0) 52.0 (50.0 to
Stride length, m/stride
Pain group 1.25 (1.13 to 1.39) 1.17 (1.09 to
Pain-free group . . . . . .
aData summaries are median (interquartile range: 25th-75th percentiles).
bValues during time 1 were obtained during pain-free ambulation in the pa
cValues for time 2 were obtained during painful ambulation in the pain groworkload.32 Because the pain-free group ambulated at a ielatively high intensity equal to 72% of their peak oxygen
ptake during the second minute of exercise, it is not
urprising that they experienced a gradual increase in oxy-
en uptake, referred to as the slow component of the
ake (VO2) during a 6-minute walk test in the pain group
e pain group was defined as the VO2 measured during
n. The change in the pain-free group was defined as the
ed during the second minute. The horizontal line in the
borders of the box mark the 75th and 25th percentiles,
m. The dots represent the observed data points.
minute walk test in the pain-group (n  33) and pain-
Change
P
(time 2 – time 1)
Change
score
Difference between
scores
) 3.5 (2.5 to 4.6) .0001 .025
) 2.3 (1.5 to 3.2) .0001
) 0.05 (0.02 to 0.07) .0001 . . .
. . . . . .
) 0.04 (0.02 to 0.06) .0001 .36
) 0.05 (0.03 to 0.07) .0001
) 4.4 (13.3 to 1.7) .0001 . . .
. . . . . .
) 1.0 (1.5 to 0.0) .0003 .79
) 0.0 (1.0 to 0.0) .0078
) 0.05 (0.14 to 0.02) .0001 . . .
. . . . . .
up and during the second minute of ambulation in the pain-free group.
during the fifth minute of ambulation in the pain-free group.n upt
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Volume 54, Number 5 Gardner et al 1371served in PAD individuals walking on a treadmill at a
constant work rate.33
Our data show a lack of agreement between the clau-
dication onset time and peak walking time obtained during
a standardized treadmill test and the pain-free time and
distance obtained during the 6-MWT. Although 33 individ-
uals experienced claudication during the 6-MWT, and there-
fore had shorter pain-free walking time and distance than the
17 participants who did not experience claudication, there
were no group differences in claudication onset time and
peak walking time values during treadmill exercise. This
supports our previous finding that there is no significant
correlation between the pain-free distance during the
6-MWT and the claudication onset time and peak walking
time obtained during a standardized treadmill test.22 This
Table V. Multiple regression model predicting the change
33 individuals in the pain group
Variables
ReDependent Independent

VO2
b Age, years
Metabolic syndromea
6-MWD, total meters
Minute 2 VO2
b
Height, cm
6-MWD, 6-minute walk distance; CI, confidence interval
aNo syndrome reference.
bCalculated as mL/kg/min.
Fig 2. Box and whisker plots show the change in oxygen
and without metabolic syndrome in the pain group. Th
painful ambulationminus the value obtained during pain-
indicates the median; the top and bottom borders of the b
whiskers mark the minimum and maximum. The dot in tsuggests that the two tests measure different aspects of tmbulatory function in individuals with PAD and clau-
ication.
The average, freely chosen walking speed during the
-MWT was 	2.5 mph, which was higher than the 2.0-
ph speed during the treadmill test; thus, the 6-MWT was
erformed at a higher exercise intensity during the first few
inutes than the treadmill test, and it is not surprising that
wo-thirds of the participants (ie, pain group) experienced
laudication sooner during the 6-MWT than during the
readmill test. However, it is surprising that one-third of
he participants (ie, pain-free group) did not experience
laudication during the 6-MWT, even though they walked
t a faster pace than during the treadmill test.
Although both groups attempted to walk as fast as they
ould during the 6-MWT, it is possible that individuals in
xygen uptake (VO2) after the onset of claudication in the
on coefficient 95% CI P
.064 0.022 to 0.11 .0041
.83 2.93 to 0.71 .0023
.0093 0.0033 to 0.015 .0037
.20 0.049 to 0.36 .012
.014 0.061 to 0.033 .54
ke (VO2) during a 6-minute walk test in participants with
nge in VO2 was defined as the value measured during
mbulation. The horizontal line in themiddle of each box
ark the 75th and 25th percentiles, respectively; and the
ddle of each box indicates the mean.in o
gressi
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November 20111372 Gardner et alduring the 6-MWT and that the walking speed during the
treadmill test was relatively too slow for them. When ex-
pressed as per distance traveled, walking too slow is equally
inefficient as walking too fast, thereby decreasing effi-
ciency.17 Thus, the faster pace during the 6-MWT may
have been more comfortable for the pain-free group than
the slower pace during the treadmill test, even though a 2%
incline was added after the first 2 minutes of the treadmill
test.
Predictors of the pain-mediated change in oxygen
uptake. Oxygen uptake increased after the onset of clau-
dication in individuals ambulating during a 6-MWT. Met-
abolic syndrome was a predictor of the pain-mediated
change in oxygen uptake. This finding suggests that insulin
resistance may interfere with central and peripheral factors
affecting the kinetics of oxygen uptake. For example, type 2
diabetes slows whole-body oxygen uptake kinetics and
heart rate kinetics during exercise,34 slows oxidative en-
zyme activity,35 increases the frequency of mitochondrial
DNA deletions in skeletal muscle,36 impairs endothelial
function,37 reduces leg blood flow during steady-state ex-
ercise,38 and slows microvascular blood flow kinetics.39
Data from our laboratory also support these findings: reac-
tive hyperemic calf blood flow is blunted in PAD patients
with metabolic syndrome compared with those without
metabolic syndrome, and they have more limited 6-MW
performance.40
Additional factors predictive of the change in pain-
mediated oxygen uptake were age, 6-MWD, and the oxy-
gen uptake during the second minute of the test. The
increase in oxygen uptake was greater in older individuals,
in those who maintained a fast pace during the test even
after pain onset to achieve a longer total distance, and in
those who had high oxygen uptake values during the early
phase of the test.
Limitations. This study has several limitations. The
regression coefficients calculated between oxygen uptake
and clinical characteristics and baseline exercise perfor-
mance measures from this cross-sectional design do not
allow causality to be established. The present findings are
also limited by the relatively small sample sizes, particularly
in the pain-free group.
Potential group differences in comorbid conditions
were not included in this study, such as arthritis, chronic
obstructive pulmonary disease, and congestive heart failure,
which may partially explain the group difference in the
change in oxygen uptake during the 6-MW. However,
these comorbid conditions would be of minimal impor-
tance unless the prevalence of these conditions was differ-
ent between groups. Furthermore, the effect of these con-
ditions (eg, arthritic pain) would typically be present
throughout the entire walking test, thereby not eliciting an
increase in oxygen uptake at any particular point during the
test like we found for the onset of claudication.
In addition, this study is limited to PAD participants
who have claudication, and may not be generalized to
individuals with less severe or more severe PAD. However,
the participants in the current study are typical of those withlaudication, because there was a good proportion of
omen and African Americans, and a high prevalence of
ardiovascular risk factors for PAD, including smoking,
iabetes, hypertension, dyslipidemia, and obesity. Thus,
he findings of the present study appear generalizable to
ndividuals with claudication who typically have numerous
omorbid conditions.
ONCLUSIONS
Claudication increases oxygen uptake of self-paced,
ver-the-ground ambulation, despite a decrease in ca-
ence. The pain-mediated increase in oxygen uptake was
lunted in participants with metabolic syndrome, suggest-
ng that they have an impaired ability to increase oxygen
ptake during ambulation. The clinical significance is that
laudication increases the metabolic cost of ambulation,
hereby increasing the relative intensity of exercise and
educing the tolerance to sustain ambulation. This infor-
ation is clinically relevant to exercise professionals who
ehabilitate patients with PAD, because the training inten-
ity should be reduced to compensate for the expected
ncrease in intensity during painful ambulation, thereby
roviding a safer and more effective exercise prescription. A
ong-term goal is to determine whether the efficacy of
nterventions designed to improve claudication translates
o improved self-paced, over-the-ground ambulation, evi-
ent by delayed occurrence of pain and by attenuation of
he increase in oxygen uptake, as individuals transition from
ain-free to painful ambulation.
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